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Psoriasis in history
References to psoriasis date to biblical 
times (Holubar, 2003). The condition is 
characterized by the relentless appear­
ance of inflamed scaly patches of skin. 
The erythema associated with chronic 
plaques is the macroscopic manifesta­
tion of ongoing recruitment and activa­
tion of T cells that sustain a permanent 
inflammatory milieu, which ultimately 
stimulates keratinocytes into hyper­
proliferation and a vicious proinflam­
matory cycle (Nograles et al., 2010). 
The ultimate cause of psoriasis remains 
unknown, and a strict mitigating sig­
nal or single antigenic target has yet 
to be identified. Together, human and 
animal studies have led to the under­
standing that in patients genetically 
susceptible to psoriasis, some stimu­
lus, perhaps infection, leads to a coor­
dinated series of cytokine signaling 
events among keratinocytes, endothe­
lial cells, T cells, macrophages, and 
dendritic cells, which, once initiated, 
sustains the cycle. Intervention at 
several points in this cycle results in 
clinical resolution; however, durable 
remissions and permanent clearance 
have not been achieved.
can regulatory t cells become IL-17 
producers in psoriasis spontaneously?
Th17 cells are a newly recognized lin­
eage of T helper cells (Harrington et 
al., 2005; Park et al., 2005) that have 
been linked to pathogenic inflam­
matory processes and autoimmune 
diseases (Goodman et al., 2009; Rizzo 
et al., 2011). In their current article, 
Bovenschen et al. demonstrate that 
regulatory T cells (Tregs) in psoriatic 
patients can differentiate toward IL­17­
expressing Tregs. The invest i gators 
suggest that the combination of psori­
atic Treg dysfunction (Sugiyama et al., 
2005) and a propensity for differenti­
ating into IL­17­producing regulatory 
cells contributes to the perpetuation 
of chronic autoimmunity. Interestingly, 
the investigators demonstrate dermal 
IL17+ Foxp3+ CD4+ Tregs in psoriatic 
skin lesions, confirming the possibil­
ity that Treg cells in disease probably 
become pathogenic IL­17 producers.
Under normal conditions, Tregs 
suppress inflammation, but numer­
ous publications have demonstrated 
a dysfunction of Tregs, particularly 
in autoimmune diseases (Bettini and 
Vignali, 2009). Bovenschen et al. have 
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identified another mechanism behind 
the propensity of autoimmune diseases 
to alter the fine balance between regu­
latory and pathogenic T cells.
Balancing Foxp3/rorgt levels
Bovenschen et al. (2011) demonstrate 
that psoriatic Tregs exhibit a propensity 
to alter levels of the master regulator 
Foxp3. They observed that upregulating 
the expression of RORgt in Tregs as 
modeled by the addition of cytokines 
representative of the psoriatic milieu 
(IL­2, IL­15, IL­1b, and IL­23), together 
with T cell receptor stimulation through 
anti­CD3/CD28, favors a concomitant 
decrease in Foxp3 and an increase of 
IL­17­producing Tregs. These investiga­
tors further demonstrate that the con­
version from Treg to IL­17/Treg is not 
an all­or­nothing transition. Indeed, it 
is likely that a continuum of converting 
cells exists, as evidenced by Foxp3+ 
RORgt+ coexpression and a gradual 
loss of Foxp3.
conversion to IL-17/treg
This observation introduces a new 
concept in psoriasis research: a cell con­
tinuum in which pure Foxp3­expressing 
Tregs coexist in the vicinity of psoriatic 
lesions with dual Foxp3­ and RORgt­
expressing Tregs that ultimately con­
verge into the IL­17­expressing Tregs, 
potentially becoming Th17 over time, 
driven by the psoriatic cytokine milieu 
(Figure 1). The data presented identify 
IL­23 as the cytokine primarily responsi­
ble for this conversion. Interestingly, this 
effect is not mediated by IL­23’s recep­
tor, suggesting that IL­23 might promote 
this conversion through an alternative 
pathway. Indeed, IL­23 seems to play a 
pivotal role in downregulating expres­
sion of Foxp3, a key feat that IL­1b and 
IFN­g are not able to achieve. Still open 
for debate is whether conversion is initi­
ated by Foxp3low or Foxp3high Tregs.
If, as the investigators propose, 
the conversion of Tregs into IL­17­
producing Tregs is a second important 
concept in regulatory cell dysfunc­
tion in psoriasis, this conversion may 
represent a window of opportunity 
for clinical interventions aimed at 
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delaying or halting the transition. 
Indeed, an examination of patients 
currently receiving therapeutics target­
ing IL­12/23p40 is called for in light of 
this new information. If these therapies 
prevent conversion, it may present a 
new mechanism of action for such bio­
logics. Many questions arise from these 
observations. For example, is it pos­
sible to reverse the phenotype of IL­17­
expressing Treg into Foxp3high Tregs? Are 
there drivers of the reconversion, such 
as IL­25 or IL­27, or is programmed 
cell death of Th17­expressing Tregs the 
only solution (Figure 1)?
are epigenetic changes necessary for 
IL-17/treg conversion?
Another observation is perhaps even 
more intriguing. Bovenschen et 
al. (2011) demonstrate in psoriatic 
Tregs, as they have previously shown 
in nonpsoriatic Tregs/IL­17 cells, 
that addition of the histone/protein 
deacetylase inhibitor trichostatin A 
can block the conversion of Foxp3+ 
Tregs into Foxp3–RORgt+ IL­17/
Tregs. This implicates histone/protein 
deacetylation as a key factor in the 
conversion of regulatory T cells to 
potentially pathogenic effector T cells. 
This is intriguing given the report of 
increased levels of histone deacety­
lase 1 (HDAC1) in psoriatic tissue 
(Tovar­Castillo et al., 2007) and the 
proposed therapeutic use of HDAC 
inhibitors for autoimmune diseases 
on the basis of their anti­inflammatory 
properties (Dinarello et al., 2011).
Thus, the work presented by 
Bovenschen and colleagues reveals 
interesting results with clinical implica­
tions for improved therapeutic agents 
designed to inhibit the conversion of 
Tregs in psoriasis. The proposed use of 
HDAC inhibitors for autoimmune dis­
eases such as systemic lupus erythema­
tous, another autoimmune disease 
with a described defect in Tregs, might 
doubly benefit from agents that may 
restore the Foxp3/RORgt balance 
toward functional regulation by Tregs 
(Reilly et al., 2011).
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Figure 1. the regulatory cell continuum mediates psoriatic pathogenesis. Foxp3 T regulatory 
cells (Tregs) convert progressively to IL­17­producing regulatory cells driven by psoriatic cytokines, 
predominantly IL­23. The fine balance between the Treg master regulatory Foxp3 and RORgt controls the 
cellular fate of Tregs.
Clinical Implications
•  Psoriatic regulatory T cells (Tregs), influenced by a psoriatic cytokine 
milieu, have an enhanced propensity to secrete the proinflammatory 
cytokine IL-17.
•  Treg plasticity is directed by the balance of Foxp3 and RORgt signaling.
•  Inhibition of histone deacetylase (HDAC) activity blocks the conversion 
of Tregs to IL-17/Tregs, suggesting that HDAC inhibitors may have 
therapeutic benefit in treating psoriasis.
